АСПЕКТЫ ПРИМЕНЕНИЯ ПЕГФИЛГРАСТИМА ПРИ ПРОВЕДЕНИИ ХИМИОТЕРАПИИ ПАЦИЕНТОВ С СОЛИДНЫМИ ОПУХОЛЯМИ
- Авторы: Абрамов М.Е1
-
Учреждения:
- Российский онкологический научный центр им. Н.Н. Блохина РАМН, Москва
- Выпуск: № 8 (2013)
- Страницы: 31-34
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/281111
- ID: 281111
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Наиболее частым побочным эффектом химиотерапии злокачественных опухолей является нейтропения. Нейтропения и фебрильная нейтропения (ФН) - главные факторы риска заболеваемости и смертности при инфекционных осложнениях. Профилактическое использование рекомбинантных человеческих гранулоцитарных колониестимулирующих факторов позволяет значительно уменьшить риски развития ФН и связанных с ней осложнений.
Ключевые слова
Полный текст
Об авторах
М. Е Абрамов
Российский онкологический научный центр им. Н.Н. Блохина РАМН, Москвак.м.н., с.н.с.
Список литературы
- Link B.K., Budd G.T., Scott S., et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer. 2001;92:1354-67.
- Lyman G.H., Crawford J., Dale D., et al. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy. Proc Am Soc Clin Oncol 2001;20:349A. Abstract 1571.
- Zelenetz A.D., Delgado D.J., Reider P.A. Review of patterns of care among community physicians in intermediate grade NHL (IGL) reveals significantly greater planned and delivered dose attenuation in older patients. Blood 2000;96:137A. Abstract 588.
- Morrison V.A., Picozzi V., Scott S., et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47-56.
- Crivellari D., Bonetti M., Castiglione-Gertsch M., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen in elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412-22.
- Aapro M.S., Bohlius J., Cameron D.A., et al, 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
- Eur J Cancer 2011;47(1):8-32. Epub 2010 Nov 20.
- Henk H.J., Becker L., Tan H., et al. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 2012 Sep 27. [Epub ahead of print].
- Zwick C., Hartmann F., Zeynalova S., et al. Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Annals of oncology 2011;22:1872-77.
- Naeim A., Henk H.J., Becker L., V. Chia., et al. Use Associated with Lower Risk of Hospitalization Than Filgrastim Use: A Retrospective US Claims Analysis. Blood (ASH Annual Meeting Abstracts) 2010;116:Abstract 3801.
- Dominguez-Gil A., Alegre A., Lopez A., et al. Cost-effectiveness analysis of febrile neutropenia (FN) prophylaxis with pegfilgrastim in non-Hodgkin's lymphoma (NHL) patients treated with chemotherapy in Spain, Eur J Hosp Pharm 2012;19:204-05. doi: 10.1136/ejhpharm-2012-000074.314.
- Ramaekers R.C., Olsen J., Obermiller A.M., et al. Efficacy and safety of half-dose pegfilgrastim in cancer patients receiving cytotoxic chemotherapy. ASCO Annual Meeting Proceedings (Post-Meeting Edition).J Clin Oncol 2012;30(15):9110.
- Hecht J.R., Pillai M., Gollard R., et al. A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy. J Clin Colorectal Cancer CIG Media Group, L.P. 2010;9(2):95-101.
- NCCN Clinical practice guidelines in oncology myeloid growth factors NCCN v.1.2012.
- Kirshner J.J., Heckler C.E., Janelsins M.C., et al. Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2010,June 4-8.Leung M., Eustaquio J., Kano J., et al. Pain severity and impairment of activity between pegfilgrastim and fixed-dose filgrastim in women with early-stage breast cancer receiving chemotherapy. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2012;30(15)0:e19570.
- Jenkins P., Scaife J., Freeman S. Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 2012;23(7):1766-71. doi: 10.1093/annonc/ mdr493. Epub 2011 Nov 2.
- Cooper K.L., Madan J., Whyte S., et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011;11:404. Published online 2011 September 23.
Дополнительные файлы
